Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ENLV | US
0.01
0.66%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.53
1.62
1.63
1.49
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona Israel.
View LessPositive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
78.3%1 month
70.5%3 months
69.5%6 months
69.8%-
-
1.22
0.03
0.03
-1.49
-
-
-17.89M
32.75M
32.75M
-
-
-
-
-61.17
0.70
0.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.37
Range1M
0.39
Range3M
0.61
Rel. volume
2.10
Price X volume
328.89K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 0.8092 | 35.57M | 3.88% | n/a | 25.98% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 2.4 | 35.40M | 8.35% | 1.29 | 0.19% |
| QNCX | QNCX | Biotechnology | 0.8165 | 35.34M | 2.70% | n/a | 30.62% |
| OCUP | OCUP | Biotechnology | 1.33 | 34.84M | 0.76% | n/a | 0.00% |
| IN8bio Inc. Common Stock | INAB | Biotechnology | 0.475 | 34.46M | 75.28% | n/a | 43.30% |
| vTv Therapeutics Inc | VTVT | Biotechnology | 14 | 34.06M | -0.99% | n/a | 1.55% |
| OKYO Pharma Limited | OKYO | Biotechnology | 0.98 | 33.16M | -3.92% | n/a | -107.88% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 3.7 | 33.01M | 5.11% | n/a | 0.00% |
| Dyadic International Inc | DYAI | Biotechnology | 1.11 | 32.72M | -4.38% | n/a | 175.64% |
| Acasti Pharma Inc | ACST | Biotechnology | 3.22 | 32.65M | -3.30% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.49 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.22 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 69.47 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 32.75M | - | Emerging |